Showing 6481-6490 of 7080 results for "".
- Mission Pharmacal Unveils New Lotion for Seborrheic Dermatitishttps://practicaldermatology.com/news/20140930-mission_pharmacal_unveils_new_lotion_for_seborrheic_dermatitis/2459100/To help bring a treatment option to people afflicted with common skin disorders including seborrheic dermatitis (SD), Mission Pharmacal Company has unveiled Ovace Plus Lotion (sodium sulfacetamide 9.8%). Ovace Plus Lotion joins Ovace Plus Wash (sodium sulfacetamide 10%) Cleansing Gel and Ovace Plus
- Taclonex Granted New Indication for Scalp Plaque Psoriasis in Adolescent Patientshttps://practicaldermatology.com/news/20140930-combination_topical_treatment_approved_for_scalp_plaque_psoriasis_in_adolescent_patients/2459101/LEO Pharma Inc., has received a new indication for Taclonex® (calcipotriene and betamethasone dipropionate) Topical Suspension for a topical combination treatment of plaque psoriasis of the scalp in patients 12 to 17 years. The new indication represents the first indication for adolescent patients a
- Provectus: PV-10 Abstract Published; New Presentation Plannedhttps://practicaldermatology.com/news/20140924-provectus_pv-10_abstract_published_new_presentation_planned/2459106/The ESMO abstract entitled, "Subgroup efficacy in patients receiving intralesional rose bengal to all existing melanoma in phase II study PV-10-MM-02," to be presented at the European Society for Medical Oncology 2014 Congress, is now
- AppForMyPatients Now Available: Personalized Apps for Aesthetic Practiceshttps://practicaldermatology.com/news/20140922-appformypatients_now_available_personalized_apps_for_aesthetic_practices/2459112/A new patent pending mobile app Nano 2.0 Business Press, LLC aims to allow dermatologists and plastic surgeons to meet the growing patient demand for mobile applications. AppForMyPatients is a software as a service (saas) platform for d
- AMA Calls for Design Overhaul of Electronic Health Records to Improve Usabilityhttps://practicaldermatology.com/news/20140917-ama_calls_for_design_overhaul_of_electronic_health_records_to_improve_usability/2459115/The AMA has called for solutions to EHR systems that have neglected usability as a necessary feature. Physicians need better designed EHR systems, the AMA has responded by releasing a new framework outlining eight priorities for improving EHR usability to benefit caregivers and patients.<
- The ISDS Awards Scholarships to Young Doctors from Around the Worldhttps://practicaldermatology.com/news/20140917-the_isds_awards_scholarships_to_young_doctors_from_around_the_world/2459117/20 young doctors have been awarded generous scholarships from twenty leaders of the International Society for Dermatologic Surgery (ISDS) to attend an ISDS medical conference. This year, the scholarships were awarded to young doctors from Europe, Asia, Latin America (including Cuba), and
- Provectus: PV-10 Clinical Data On The Treatment Of Melanoma To Be Presented At ESMO 2014https://practicaldermatology.com/news/20140915-provectus_pv-10_clinical_data_on_the_treatment_of_melanoma_to_be_presented_at_esmo_2014/2459120/Provectus Biopharmaceuticals, Inc. will present clinical data on PV-10 at the European Society for Medical Oncology's 2014 Congress (ESMO) in Madrid, Spain. The presentation, titled "Subgroup efficacy in patients receiving intralesional rose bengal t
- Cynosure Acquires Assets of RF Medical Device Manufacturer Ellman International, Inc.https://practicaldermatology.com/news/20140910-cynosure_acquires_assets_of_rf_medical_device_manufacturer_ellman_international_inc/2459121/Cynosure, Inc., which specializes in laser- and light-based aesthetic treatments for non-invasive and minimally invasive applications, has acquired the assets of Ellman International, Inc. for approximately $13.2 million in cash. In addition, Cynosure assumed certain contractual and current liab
- FDA Accepts Investigational New Drug Application for Alphaeon's Neurotoxin Evosyalhttps://practicaldermatology.com/news/20140909-fda_accepts_investigational_new_drug_application_for_alphaeons_neurotoxin_evosyal/2459123/The FDA accepted the Investigational New Drug (IND) Application to conduct clinical studies for EVOSYAL, an botulinum toxin Type A neurotoxin that was acquired by Alphaeon last year as part of the acquisition of Evolus Inc. “The product development team
- Novan's Nitric Oxide Drug Candidate Inhibits Growth of Papillomavirus in Translational Animal Model: Presentationhttps://practicaldermatology.com/news/20140909-novans_nitric_oxide_drug_candidate_inhibits_growth_of_papillomavirus_in_translational_animal_model_presentation/2459124/Novan Therapeutics, a clinical-stage biotech company focused on advancing nitric oxide therapies, announced that Novan's nitric oxide drug candidate SB206 was shown to inhibit papilloma growth in a preclinical animal study. About two-thirds of healthy American adults are infected with human papillom